Similar articles for PMID: 10449548

Year	Number of Results
1979	1
1981	3
1982	3
1983	4
1985	4
1986	3
1987	2
1988	2
1989	3
1990	2
1991	6
1992	9
1993	12
1994	16
1995	16
1996	14
1997	13
1998	10
1999	15
2000	17
2001	8
2002	2
2003	6
2004	4
2005	5
2006	5
2007	8
2008	4
2009	6
2010	2
2011	8
2012	7
2013	4
2014	9
2015	6
2016	5
2017	5
2018	5
2019	16
2020	10
2021	14
2022	16
2023	5
2024	0

1

Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B Jr, Wanders RJ, Barth PG. van Geel BM, et al. J Neurol Neurosurg Psychiatry. 1999 Sep;67(3):290-9. doi: 10.1136/jnnp.67.3.290. J Neurol Neurosurg Psychiatry. 1999. PMID: 10449548 Free PMC article. Clinical Trial.

2

A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy.

Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaqué I, Jakobezak C, Lemaitre A, Boureau F, Wolf C, et al. Aubourg P, et al. N Engl J Med. 1993 Sep 9;329(11):745-52. doi: 10.1056/NEJM199309093291101. N Engl J Med. 1993. PMID: 8350883 Free article. Clinical Trial.

3

Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil.

Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB, Xu J, Jones RO, Loes DJ, Melhem ER, Dubey P, Bezman L, Brereton NH, Odone A. Moser HW, et al. Arch Neurol. 2005 Jul;62(7):1073-80. doi: 10.1001/archneur.62.7.1073. Arch Neurol. 2005. PMID: 16009761

4

Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.

Deon M, Garcia MP, Sitta A, Barschak AG, Coelho DM, Schimit GO, Pigatto M, Jardim LB, Wajner M, Giugliani R, Vargas CR. Deon M, et al. Metab Brain Dis. 2008 Mar;23(1):43-9. doi: 10.1007/s11011-007-9079-9. Epub 2007 Nov 17. Metab Brain Dis. 2008. PMID: 18026827

5

Dietary management of X-linked adrenoleukodystrophy.

Moser HW, Borel J. Moser HW, et al. Annu Rev Nutr. 1995;15:379-97. doi: 10.1146/annurev.nu.15.070195.002115. Annu Rev Nutr. 1995. PMID: 8527226 Review.

6

The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.

Deon M, Wajner M, Sirtori LR, Fitarelli D, Coelho DM, Sitta A, Barschak AG, Ferreira GC, Haeser A, Giugliani R, Vargas CR. Deon M, et al. J Neurol Sci. 2006 Sep 25;247(2):157-64. doi: 10.1016/j.jns.2006.04.004. Epub 2006 Jun 5. J Neurol Sci. 2006. PMID: 16750542 Clinical Trial.

7

Adrenoleukodystrophy: magnetic resonance follow-up after Lorenzo's oil therapy.

Duchesne N, Dufour M, Bouchard G, Grondin P, Lemieux B. Duchesne N, et al. Can Assoc Radiol J. 1995 Oct;46(5):386-91. Can Assoc Radiol J. 1995. PMID: 7552831

8

Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?

Cappa M, Bizzarri C, Giannone G, Aiello C, Di Biase A. Cappa M, et al. J Endocrinol Invest. 2011 Nov;34(10):753-6. doi: 10.3275/7570. Epub 2011 Mar 7. J Endocrinol Invest. 2011. PMID: 21399389

9

Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy.

Moser HW. Moser HW. J Neuropathol Exp Neurol. 1995 Sep;54(5):740-5. doi: 10.1097/00005072-199509000-00017. J Neuropathol Exp Neurol. 1995. PMID: 7666063 Review.

10

A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.

Ahmed MA, Kartha RV, Brundage RC, Cloyd J, Basu C, Carlin BP, Jones RO, Moser AB, Fatemi A, Raymond GV. Ahmed MA, et al. Br J Clin Pharmacol. 2016 Jun;81(6):1058-66. doi: 10.1111/bcp.12897. Epub 2016 Apr 3. Br J Clin Pharmacol. 2016. PMID: 26836218 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

299 results

Results by year